FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.
Sponsor: Assistance Publique - Hôpitaux de Paris
You may qualify if…
- ✓ Adult subjects aged 18 years and older
- ✓ Adenocarcinoma of the middle and/or lower rectum pMMR T3, T4, and/or N+
- ✓ Resectable synchronous liver metastases
You may not qualify if…
- ✕ Minor under the age of 18.
- ✕ Presence of extrahepatic metastases
- ✕ Induction chemotherapy with FOLFIRINOX of less than 2 courses
Source: ClinicalTrials.gov · NCT07467434 · last updated 2026-06-09